Related coverage linked through entity extraction aliases.
Jul 06, 2026
Novartis acquires UK biotech Myricx Bio for up to $1.5B, gaining a novel NMTi ADC payload platform and two lead assets targeting B7-H3 and HER2. The deal includes $1.1B upfront with $400M in milestones, expected to close in H2 2026.
Jul 03, 2026
The FDA will allow food makers to claim "no artificial colors" as long as dyes are not petroleum-based, even if products contain titanium dioxide. Health experts warn the labeling deceives consumers, as naturally derived additives like titanium dioxide pose health risks and remain unregulated.
Jul 03, 2026
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
Jul 01, 2026
The U.S. five-year cancer survival rate reached 70% in 2025, creating 18.6 million survivors. Health systems are expanding survivorship care using advanced practice providers and investing over $4 billion in oncology infrastructure to meet growing demand.
Jun 29, 2026
Scientists have identified SLAMF6 as a key suppressor of T cell immunity against cancer and developed monoclonal antibodies that neutralize it in mice, published in Nature. Biotechnology company Replimune Group has reported its 2026 financial position, with a market value of approximately $234.5 million and ongoing clinical trials.
Jun 25, 2026
Research has identified CD27 expression as a potential biomarker for monitoring regulatory T cell (Treg) induction efficacy in clinical trials. Studies show CD27 marks memory-like Tregs with superior suppressive capacity, correlating with immune regulation in type 1 diabetes patients. Treg-based tolerance restoration is emerging as a therapeutic strategy for autoimmune diseases and transplantation.
Jun 25, 2026
University of Alberta researchers have identified the protease GlpG as a new drug target for antibiotic-resistant E. coli, which causes hundreds of thousands of UTI deaths annually. Inhibiting GlpG prevented bacterial adhesion and biofilm formation in laboratory studies. The discovery addresses a global health emergency as antimicrobial resistance projections show it could cause cancer-level deaths by 2050.
Jun 24, 2026
Brazilian researchers developed a CT-based biomarker called VMD that combines visceral fat and muscle radiodensity to predict gastric cancer prognosis, with patient survival ranging from 13.8 to 58.5 months. The global PET imaging market is projected to grow to $1.4 billion by 2032 as cancer cases rise globally. Neuroendocrine tumor research is advancing with new funding and studies on Hedgehog signaling pathways.
Jun 23, 2026
New rankings from WIPR and IAM Patent 1000 recognize top US patent firms and lawyers, highlighting expertise in pharmaceutical litigation, tech disputes, and strategic portfolio management amid shifting PTAB procedures and rising NPE campaigns in life sciences.
Jun 23, 2026
The Fonds pour l'Innovation et le Futur de Genève (FIF) has awarded funding to six Geneva-based startups across two rounds, including Backbone, Crìa Technologies, Scenario X, Flottando, Axy, and Nose Switzerland, supporting innovations in AI, quantum computing, fleet management, and life sciences.
Jun 22, 2026
ChemT Biotechnology closed a $4 million seed round led by Wavemaker Ventures to advance its AI-driven biomanufacturing platform. The company's CelMo™ platform demonstrated a 50% increase in antibody output in CHO cells. ChemT plans to expand its technology to stem cells, NK cells, and HEK cells.
Jun 20, 2026
Nova Scotia Health has reduced radiation therapy hours at the Halifax cancer centre due to 14 radiation therapist vacancies, with up to 48 appointments going unfilled daily. A proposed 10-seat training program at Dalhousie University was rejected by the treasury board despite a looming workforce retirement wave. Advocates warn the staffing shortage will worsen as Nova Scotia's high cancer rates continue to grow.
Jun 21, 2026
The FDA now allows "no artificial colors" labeling claims for foods without FD&C-certified synthetic colors, part of federal efforts to transition away from petroleum-based dyes. The agency approved beetroot red and expanded spirulina extract uses while initiating a safety review of preservative BHA.
Jun 18, 2026
Immune checkpoint inhibitors are associated with a significantly lower risk of non-neovascular age-related macular degeneration, while sociodemographic disparities strongly influence diabetic retinopathy screening adherence, according to two separate ophthalmology studies.
Jun 17, 2026
The American College of Sports Medicine has published the first evidence-based exercise guidelines for children and adolescents with cancer, recommending safe, supervised activity during treatment. A new clinical trial is also evaluating structured exercise for young sarcoma patients undergoing chemotherapy to improve outcomes and quality of life.
Jun 12, 2026
Two Chinese pharmaceutical companies have reported new inhibitor discoveries in recent patents. Changchun Genescience Pharmaceuticals identified FGFR2/3 inhibitors for cancer and bone disorder treatment, while Hengrui Pharmaceuticals disclosed new SNF2L2 inhibitors potentially useful for cancer therapy.
Jun 11, 2026
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
Jun 10, 2026
Onco-Innovations has begun scaling production of A83B4C63, the API in its lead cancer drug ONC010, to kilogram quantities at Dalton Pharma Services' Toronto facility to support IND-enabling studies. The company's subsidiary Inka Health signed AI research agreements with AstraZeneca and GlaxoSmithKline, and plans a first-in-human study in 2026 pending a pre-IND meeting with the FDA.
Jun 09, 2026
The Australian government announced an additional $387.4 million for CSIRO over four years and $12.7 million for eight quantum technology projects under the Critical Technologies Challenge Program, part of its broader National Quantum Strategy commitment.
Jun 09, 2026
NASA announced the four-member Artemis III crew, who will test lunar lander rendezvous and docking operations ahead of the 2028 moon landing attempt. The mission faces uncertainty as Blue Origin recovers from a launch pad explosion and SpaceX continues developing its lander system. Space medicine experts note that deeper missions will require astronauts to manage medical care independently without Earth support.
